A Phase 2 interventional study of Rituximab and Atacicept in Rheumatoid Arthritis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-30.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 197th largest by enrollment of the 222 interventional ones that give a count, is one of 18 that started in 2008, is one of 33 in phase 2, and was the 44th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
University Hospital, Tours · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
357 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 37 · Phase 3 75 · Phase 4 37
First in 2000; this study’s year is marked. 18 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 167 across the 222 interventional studies, 271 across the 134 observational. Of the 261 that completed or were terminated, 99 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
174 of 357 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
| NCT04870203Phase 3University Hospital, BordeauxCombination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | 2027-03 |
| NCT07321340Centre Hospitalier Universitaire de Saint EtienneInsole Optimization for Rheumatoid Arthritis Patients | 2026-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT04292067Assistance Publique - Hôpitaux de ParisCharacterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis | 2026-11 |
Add all 16 to your calendar (.ics) → With an account.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and tolerability of combined treatment with atacicept and rituximab in subjects with active rheumatoid arthritis (RA) receiving re-treatment with rituximab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
Biological: Rituximab · Drug: Atacicept
Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
Biological: Rituximab · Drug: Placebo matched to atacicept
Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
Time frame: Baseline up to Week 64
Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L)
Time frame: Week 64
Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32
Vital signs assessed included blood pressure (systolic and diastolic), pulse and body temperature. Routine safety lab parameters evaluated included red blood cell (RBC), hemoglobin, hematocrit, platelets, mean cellular hemoglobin (MCH), MCH concentration, MCH volume, white blood cell (WBC), lymphocytes, monocytes, eosinophils, basophils, neutrophils, gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, glucose, potassium, total protein, sodium, uric acid, and blood urea nitrogen. Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.
Time frame: Baseline, Week 32
Percent Change From Baseline in Anti-tetanus and Anti-diphteria Immunization Titer at Week 32
Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.
Time frame: Baseline, Week 32
Percent Change From Baseline in Anti-pneumococcus Titer at Week 32
Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.
Time frame: Baseline, Week 32
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP), ACR50-CRP and ACR70-CRP at Week 32
ACR20-CRP response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP). ACR50-CRP and ACR70-CRP response are defined as \>=50% and \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) respectively together with \>=50% and \>=70% improvement in at least 3 of the following respectively: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) CRP.
Time frame: Week 32
Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) at Week 32
DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 score ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.
Time frame: Baseline, Week 32
Median Percentage Change From Baseline in Levels of Total, Mature and Memory B Cells
Flow cytometric analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of total, mature and memory B cell levels.
Time frame: Baseline, Week 3, 7, 12, 16, 26 and 32
| Milestone | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Started | 18 | 9 |
| Completed | 12 | 8 |
| Not completed | 6 | 1 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 1 | 0 |
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
| Participants | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| AEs | 17 | 9 |
| SAEs | 6 | 2 |
| percentage of participants | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L) | 0 | 0 |
Vital signs assessed included blood pressure (systolic and diastolic), pulse and body temperature. Routine safety lab parameters evaluated included red blood cell (RBC), hemoglobin, hematocrit, platelets, mean cellular hemoglobin (MCH), MCH concentration, MCH volume, white blood cell (WBC), lymphocytes, monocytes, eosinophils, basophils, neutrophils, gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, glucose, potassium, total protein, sodium, uric acid, and blood urea nitrogen. Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.
| Percent change | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Systolic Blood Pressure (n = 12, 9) | 3.74 ± 11.76 | -6.29 ± 13.80 |
| Diastolic Blood Pressure (n = 12, 9) | 1.09 ± 11.19 | 4.89 ± 10.09 |
| Pulse (n = 12, 9) | 10.21 ± 19.93 | -8.54 ± 11.98 |
| Temperature (n = 10, 8) | 0.23 ± 1.05 | -0.44 ± 0.86 |
| RBC (n = 12, 9) | 3.10 ± 5.30 | 4.94 ± 7.18 |
| Hemoglobin (n = 12, 9) | 2.55 ± 5.32 | 4.93 ± 6.18 |
| Hematocrit (n = 12, 9) | 2.39 ± 6.30 | 6.05 ± 6.15 |
| Platelets (n = 12, 9) | -6.80 ± 21.21 | -2.49 ± 37.62 |
| MCH (n = 12, 9) | -0.32 ± 5.03 | 0.22 ± 3.21 |
| MCH Concentration (n = 12, 9) | -0.18 ± 2.01 | -1.41 ± 1.47 |
| MCH Volume (n = 12, 9) | -0.06 ± 4.98 | 1.39 ± 2.73 |
| WBC(n = 12, 9) | -14.59 ± 36.85 | -9.70 ± 19.15 |
| Lymphocytes (n = 12, 9) | 0.27 ± 30.11 | -5.68 ± 23.00 |
| Monocytes (n = 12, 9) | 5.01 ± 70.44 | 1.88 ± 38.51 |
| Eosinophils (n = 12, 9) | 34.11 ± 103.78 | -7.51 ± 34.58 |
| Basophils (n = 12, 9) | -20.45 ± 58.61 | 32.41 ± 117.44 |
| Neutrophils (n = 12, 9) | -11.29 ± 57.75 | -13.09 ± 24.01 |
| GGT (n = 12, 9) | -3.21 ± 30.37 | 10.17 ± 53.33 |
| ALT (n = 12, 9) | 17.52 ± 27.89 | 17.79 ± 53.23 |
| Albumin (n = 12, 9) | 6.22 ± 6.34 | 6.43 ± 8.10 |
| AP (n = 12, 9) | 4.85 ± 18.86 | -5.41 ± 16.48 |
| AST (n = 12, 9) | 14.53 ± 30.87 | 6.73 ± 36.47 |
| Bilirubin Total (n = 12, 9) | 15.09 ± 42.78 | 4.76 ± 14.29 |
| Calcium (n = 12, 9) | -1.07 ± 5.04 | 2.61 ± 4.72 |
| Creatinine (n = 12, 9) | -3.29 ± 10.30 | 5.89 ± 5.26 |
| Glucose (n = 12, 9) | 3.71 ± 18.55 | 7.99 ± 22.71 |
| Potassium (n = 12, 9) | -0.93 ± 6.34 | 4.67 ± 9.37 |
| Total Protein (n = 12, 9) | -2.83 ± 7.08 | 4.17 ± 6.57 |
| Sodium (n = 12, 9) | 1.21 ± 1.46 | 0.25 ± 1.63 |
| Uric Acid (n = 12, 9) | -2.95 ± 12.60 | -0.72 ± 6.10 |
| Blood Urea Nitrogen (n = 12, 9) | 1.63 ± 27.04 | -7.42 ± 26.02 |
Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.
| percent change | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Anti-tetanus Immunization Titer | -17.98 (-34.29 to 0.00) | 0.00 (-7.67 to 23.68) |
| Anti-diphtheria Immunization Titer | -33.68 (-50.00 to 0.00) | 8.41 (0.39 to 33.93) |
Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.
| percent change | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Percent Change From Baseline in Anti-pneumococcus Titer at Week 32 | -18.49 (-35.18 to 0.00) | 0.00 (0.00 to 0.00) |
ACR20-CRP response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP). ACR50-CRP and ACR70-CRP response are defined as \>=50% and \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) respectively together with \>=50% and \>=70% improvement in at least 3 of the following respectively: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) CRP.
| percentage of participants | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| ACR20-CRP | 33.3 | 22.2 |
| ACR50-CRP | 11.1 | 11.1 |
| ACR70-CRP | 5.6 | 0 |
DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 score ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.
| Units on a scale | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Baseline (n = 18, 9) | 5.50 ± 0.99 | 5.81 ± 1.04 |
| Change at Week 32 (n = 12, 9) | 3.85 ± 0.98 | 4.25 ± 1.10 |
Flow cytometric analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of total, mature and memory B cell levels.
| percent change | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Total B cells (Week 3: n=18, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Total B cells (Week 7: n=17, 8) | -100.00 (-100.00 to -100.00) | -99.69 (-100.00 to -96.96) |
| Total B cells (Week 12: n=16, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Total B cells (Week 16: n=15, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Total B cells (Week 26: n=12, 9) | -100.00 (-100.00 to -93.06) | -94.74 (-100.00 to -71.43) |
| Total B cells (Week 32: n=12, 9) | -86.99 (-98.26 to -50.00) | -68.11 (-100.00 to -35.00) |
| Mature B Cells (Week 3: n=18, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Mature B Cells (Week 7: n=17, 8) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Mature B Cells (Week 12: n=16, 9) | -100.00 (-100.00 to -47.78) | -100.00 (-100.00 to -100.00) |
| Mature B Cells (Week 16: n=15, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Mature B Cells (Week 26: n=12, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -85.11) |
| Mature B Cells (Week 32: n=12, 9) | -99.35 (-100.00 to -22.73) | -84.47 (-100.00 to -48.94) |
| Memory B cells (Week 3: n=18, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Memory B cells (Week 7: n=17, 8) | -100.00 (-100.00 to -66.67) | -100.00 (-100.00 to -100.00) |
| Memory B cells (Week 12: n=16, 9) | -100.00 (-100.00 to -68.33) | -100.00 (-100.00 to -100.00) |
| Memory B cells (Week 16: n=15, 9) | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -66.67) |
| Memory B cells (Week 26: n=12, 9) | -100.00 (-100.00 to -82.50) | -88.89 (-100.00 to -25.00) |
| Memory B cells (Week 32: n=12, 9) | -83.33 (-100.00 to -25.00) | -50.00 (-100.00 to -44.44) |
Collected over Baseline up to Week 64. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab Plus Atacicept | — | 6/18 (33.3%) | 17/18 (94.4%) |
| Rituximab Plus Placebo | — | 2/9 (22.2%) | 9/9 (100%) |
| Event | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Transient ischaemic attackNervous system disorders | 1/18 | 1/9 |
| Ruptured cerebral aneurysmNervous system disorders | 0/18 | 1/9 |
| DemyelinationNervous system disorders | 1/18 | 0/9 |
| Nervous system disorderNervous system disorders | 1/18 | 0/9 |
| Atrial fibrillationCardiac disorders | 1/18 | 0/9 |
| Cardiac arrestCardiac disorders | 1/18 | 0/9 |
| Ventricular fibrillationCardiac disorders | 1/18 | 0/9 |
| ArthropathyMusculoskeletal and connective tissue disorders | 1/18 | 0/9 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/18 | 0/9 |
| Joint capsule ruptureInjury, poisoning and procedural complications | 1/18 | 0/9 |
| Event | Rituximab Plus Atacicept | Rituximab Plus Placebo |
|---|---|---|
| Injection site reactionGeneral disorders | 7/18 | 2/9 |
| Upper respiratory tract infectionInfections and infestations | 3/18 | 3/9 |
| Injection site erythemaGeneral disorders | 4/18 | 0/9 |
| Injection site pruritusGeneral disorders | 4/18 | 0/9 |
| HeadacheNervous system disorders | 4/18 | 1/9 |
| Back painMusculoskeletal and connective tissue disorders | 3/18 | 1/9 |
| PruritusSkin and subcutaneous tissue disorders | 3/18 | 0/9 |
| InfluenzaInfections and infestations | 2/18 | 1/9 |
| RhinitisInfections and infestations | 2/18 | 0/9 |
| Urinary tract infectionInfections and infestations | 1/18 | 1/9 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Rituximab Plus Atacicept | Rituximab Plus Placebo | Total |
|---|---|---|---|
| Mean | 57.0 ± 11.0 | 57.7 ± 11.5 | 57.2 ± 11.0 |
| Gender(Participants) | Rituximab Plus Atacicept | Rituximab Plus Placebo | Total |
|---|---|---|---|
| Female | 12 | 8 | 20 |
| Male | 6 | 1 | 7 |
The record gives a start of Mar 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein
Merck KGaA, Darmstadt, Germany →